Why Repros Therapeutics Is Poised to Pull Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage biotech company Repros Therapeutics has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Repros and see what CAPS investors are saying about the stock right now.
The Woodlands, Texas (1987)
CEO Joseph Podolski (since 1992)
CFO Katherine Anderson (since 2011)
Return on Capital (average, past 3 years)
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 52% of the 132 members who have rated Repros believe the stock will underperform the S&P 500 going forward.
A year ago I did some in depth research on Repros and concluded that at a share price of [$9.00] the stock was untouchable. I couldn't impeach their science but the company had a long-standing pedigree of misrepresentation dating back to their days as Zonagen. ...
I stood on the sidelines and today the stock stands at double where it was when I drew my prior conclusions. This comes despite a couple of notable setbacks: a data issue in the ZA-301 trial of Androxal that might be grounds for an eventual CRL, and the FDA refusal to permit the company to move directly to a phase III trial of vaginal Proellex for uterine fibroids. I think Repros has benefited from the recent forgiving mood of the market toward the biotech sector in general, but all pendulums eventually swing. A market cap of [$370M] doesn't seem like a lot compared to some other frothy companies, but I'll make a measured bet that Repros has gotten a little ahead of itself.
While you can certainly make quick gains in red-hot biotech stocks, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Repros Therapeutics Is Poised to Pull Back originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.